Apr 19, 2021

Biomica To Present at Jefferies Microbiome-Based Therapeutics Summit, on April 22nd, 2021 (Virtual Conference)

Rehovot, Israel – April 19, 2021 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), today announced that Dr. Elran Haber, Chief Executive Officer of Biomica, will present at the Jefferies Microbiome-Based Therapeutics Summit being held on Thursday, April 22, 2021.

Dr. Haber will be available for one-on-one meetings during the summit.

A Pre-Recording of the Presentation will be made available on Thursday, April 22, 2021.

***

About Biomica:

Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapeutics utilizing a dedicated Computational Predictive Biology platform (CPB), licensed from Evogene. Biomica aims to identify and characterize disease-related microbiome entities and to develop novel therapeutics based on these understandings. The company is focused on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. Biomica is a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN). For more information, please visit www.biomicamed.com.

 

Contact:

Rivka Neufeld/ Aviva Banczewski

Investor Relations and Public Relations Manager

E: IR@evogene.com

T: +972-8-931-1900

 

US Investor Relations:

Joseph Green

Edison Group

E: jgreen@edisongroup.com

T: +1 646-653-7030

Laine Yonker

Edison Group

E: lyonker@edisongroup.com

T: +1 646-653-7035

Back to all News

Highlighted News About Biomica

ASCO 2024 logo
Apr 16, 2024

American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

We’re pleased to announce that Dr. Shiri Meshner, our VP of Research and Development, will be participating in the Pharmabiotic Conference 2024. She’ll be presenting alongside Claire Derlot, Chief Business Officer of Biose Industrie, on the topic “Biomica & Biose Industrie: The clinical journey of a multi-strain LBP”. Additionally, Dr. Meshner will contribute to a panel discussion focusing on Clinical Design & Methodology.